GHRH Antagonists JMR-132 and JV-1-38 Suppress Proliferation, Induce Apoptosis in Prostate Cancer
Background
Growth hormone-releasing hormone (GHRH) and its receptors are increasingly recognized for their role in tumor progression across various cancers, including prostate cancer. Current standard-of-care treatments for advanced or androgen-independent prostate cancer often face challenges like resistance and significant side effects. Targeting the GHRH receptor pathway with antagonists offers a promising therapeutic strategy, as these compounds have demonstrated anti-tumor effects in other cancer types, suggesting a potential novel approach to inhibit prostate cancer growth and survival.
Study Design
Researchers investigated the anti-proliferative and pro-apoptotic effects of GHRH antagonists in non-tumoral RWPE-1 and tumoral LNCaP and PC3 human prostatic epithelial cells. They also used an experimental in vivo model of human PC3 tumor xenografts in nude mice. The study evaluated the effects of JMR-132 and JV-1-38 on cell viability (MTT assay), proliferation (BrdU assay), cell cycle, and apoptotic processes in PC3 cells. Expression levels of key markers like PCNA, p53, p21, CD44, Cyclin D1, c-myc, Bax, and Bcl2 were determined using Western-blot and RT-PCR in both in vitro and in vivo models.
Results
GHRH antagonists JMR-132 and JV-1-38 consistently suppressed cell proliferation and significantly decreased the levels of the proliferation marker, PCNA, across all three cell lines (RWPE-1, LNCaP, PC3) and in the PC3 tumor xenograft model. These antagonists altered cell cycle progression, leading to an increase of cells in the S-phase and a corresponding decrease in G1 and G2/M phases. This resulted in the induction of S-phase arrest and a notable increase in apoptotic cells. The observed effects on the cell cycle and apoptosis were attributed to significant changes in the expression of several key regulatory proteins. Specifically, the study found altered expression of p21, p53, Bax (pro-apoptotic), Bcl2 (anti-apoptotic), CD44, Cyclin D1, c-myc, and caspase 3. These molecular changes collectively support the role of GHRH antagonists in inhibiting cancer cell growth and promoting programmed cell death. GHRH antagonists suppressed cell proliferation and decreased the levels of the proliferation marker, PCNA, in the three cell lines and in PC3 tumor, leading to S-phase arrest and increased apoptotic cells.
Key Findings
- GHRH antagonists JMR-132 and JV-1-38 suppressed cell proliferation in RWPE-1, LNCaP, and PC3 cell lines.
- Antagonists decreased PCNA proliferation marker levels in all cell lines and PC3 tumor xenografts.
- GHRH antagonists induced S-phase arrest and increased apoptotic cells in PC3 cells.
- Changes in p21, p53, Bax, Bcl2, CD44, Cyclin D1, c-myc, and caspase 3 expression mediated these effects.
Why It Matters
This research reinforces the potential of GHRH antagonists as a novel therapeutic strategy for prostate cancer, particularly for androgen-independent forms that are often resistant to conventional treatments. The findings suggest that these compounds could be developed into drugs that not only halt cancer cell growth but actively induce their death by modulating key cell cycle and apoptotic pathways. While currently in preclinical stages, this work provides a strong mechanistic basis for further development, potentially leading to new treatment options that could improve outcomes for patients with advanced prostate cancer. Future clinical translation will require extensive safety and efficacy studies in humans, but the clear anti-proliferative and pro-apoptotic effects observed are highly encouraging.
prostate cancer
ghrh antagonist
jmr-132
jv-1-38
cell proliferation
apoptosis